There could be a potential anti-carcinogenetic mechanism for FGF21 via a negative feedback loop on the TLR4-IL-17A axis in the liver; this hypothesis was supported by the findings in which high expression of FGF21 and low expression of IL-17A were closely correlated with better prognosis in the HCC patients. Here, TLR4 is linked to hepatocellular carcinoma.